Director Veleka Peeples-Dyer filed a Form 144 notice with the SEC on October 28, 2026, disclosing a proposed sale of 12,000 shares of Replimune Group, Inc. common stock following a stock option exercise.

Key Highlights

  • Selling person: Veleka Peeples-Dyer, identified in the filing as a Director of Replimune Group, Inc.
  • Shares proposed for sale: 12,000 shares of common stock, with an aggregate market value of $154,744.80.
  • Source of shares: The securities were acquired on October 28, 2026 via a stock option exercise from the issuer, with cash payment on the same date.
  • Approximate date of sale: October 28, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Total shares outstanding: 94,800,404 shares of common stock outstanding, according to the filing.
  • Prior three-month sales: The filing reports nothing to report for securities sold during the past three months by the selling person.

Replimune Director Discloses Proposed Stock Sale Under Rule 144

According to the filing, Veleka Peeples-Dyer, a Director of Replimune Group, Inc. (NASDAQ:REPL), submitted a Form 144 notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. The notice was dated October 28, 2026, and pertains to 12,000 shares of Replimune common stock, with an aggregate market value stated in the filing as $154,744.80.

The filing discloses that the 12,000 shares were acquired on October 28, 2026 through a stock option exercise from the issuer, with the nature of payment listed as cash. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, on the approximate sale date of October 28, 2026. The filing lists the total number of shares of common stock outstanding as 94,800,404.

The filing notes that no securities of Replimune Group were sold by the filing person during the past three months. By signing the Form 144, the filing person represented, as stated in the notice, that she "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The issuer's address is listed as 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts 01801.

What Was Disclosed

Replimune Group Director Veleka Peeples-Dyer filed a Form 144 on October 28, 2026, disclosing a proposed sale of 12,000 common shares, acquired the same day via stock option exercise, with an aggregate market value of $154,744.80.